Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis
| Status: | Archived |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2009 |
| End Date: | February 2010 |
Pharmacokinetics of Invanz® (Ertapenem) in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis
Critically ill patients in the intensive care unit often receive continuous hemodialysis to
treat their kidney failure. Ertapenem is an antibiotic often used in these patients.
Continuous dialysis may remove ertapenem, putting patients at risk for inappropriate
treatment of their infection. This study will determine how much ertapenem is removed by
continuous hemodialysis.
Subjects receiving CVVHD will receive a one gram dose of ertapenem. Serial blood samples
over 24 hours will be taken to assess the ertapenem blood concentrations over time. Spent
dialysate and urine samples (if any) will also be measured for ertapenem content to
determine how much drug is removed by CVVHD and kidneys. A pharmacokinetic evaluation will
be made to determine what is the most appropriate dose for this drug in patients receiving
CVVHD to achieve pharmacokinetic and pharmacodynamic goals.
We found this trial at
1
site
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health Systems The University of Michigan is home to one of the...
Click here to add this to my saved trials
